ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
Clywedog Therapeutics (formerly Barinthus Therapeutics; NASDAQ: BRNS) and Barinthus have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. ChemDiv will continue providing chemistry, computational, and clinical pharmacology support as the combined company advances clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D) and celiac disease. The merged company is expected to list on Nasdaq under the ticker CLYD upon closing, with transaction closing targeted for the first half of 2026. The portfolio includes three clinical-stage assets and multiple near-term data milestones; ChemDiv says its services helped progress discovery programs to clinic in less than three years.
Clywedog Therapeutics (precedentemente Barinthus Therapeutics; NASDAQ: BRNS) e Barinthus hanno firmato un accordo definitivo di fusione per formare Clywedog Therapeutics, Inc. ChemDiv continuerà a fornire supporto in chimica, computazionale e farmacologia clinica mentre la società combinata avanza candidati a livello clinico nelle diabete di tipo 1 (T1D), diabete di tipo 2 (T2D) e malattia celiaca. La società fusa dovrebbe essere ammessa alla Borsa di Nasdaq con il ticker CLYD al momento della chiusura, con l'atto di chiusura della transazione previsto per la prima metà del 2026. Il portafoglio comprende tre asset in fase clinica e molteplici traguardi di dati a breve termine; ChemDiv afferma che i suoi servizi hanno contribuito a portare i programmi di scoperta in clinica in meno di tre anni.
Clywedog Therapeutics (anteriormente Barinthus Therapeutics; NASDAQ: BRNS) y Barinthus han firmado un acuerdo definitivo de fusión para formar Clywedog Therapeutics, Inc. ChemDiv continuará brindando apoyo en química, computación y farmacología clínica a medida que la empresa combinada avanza candidatas en estadio clínico en diabetes tipo 1 (T1D), diabetes tipo 2 (T2D) y enfermedad celíaca. Se espera que la empresa fusionada cotice en Nasdaq bajo el ticker CLYD tras el cierre, con el cierre de la transacción previsto para la primera mitad de 2026. El portafolio incluye tres activos en etapas clínicas y múltiples hitos de datos a corto plazo; ChemDiv dice que sus servicios ayudaron a avanzar programas de descubrimiento a clínica en menos de tres años.
Clywedog Therapeutics(구 Barinthus Therapeutics; NASDAQ: BRNS)와 Barinthus는 합병 합의서를 체결하여 Clywedog Therapeutics, Inc.를 설립하기로 했습니다. ChemDiv는 결합된 회사가 일형 당뇨병(T1D), 당뇨병 2형(T2D) 및 셀리악 질환의 임상 단계 후보를 발전시킬 때 화학, 계산 및 임상 약리학 지원을 계속 제공할 것입니다. 합병된 회사는 종가 시점에 CLYD라는 티커로 나스닥에 상장될 예정이며 거래 종결은 2026년 상반기를 목표로 하고 있습니다. 포트폴리오에는 세 가지 임상 단계 자산과 다수의 근시일 데이터 이정표가 포함되어 있으며 ChemDiv는 자사의 서비스가 발견 프로그램을 임상으로 진행하는 데 세 해 미만에 기여했다고 말합니다.
Clywedog Therapeutics (anciennement Barinthus Therapeutics; NASDAQ : BRNS) et Barinthus ont signé un accord définitif de fusion pour former Clywedog Therapeutics, Inc. ChemDiv continuera à fournir un soutien en chimie, computation et pharmacologie clinique à mesure que la société fusionnée fait progresser des candidats en phase clinique dans le diabète de type 1 (T1D), le diabète de type 2 (T2D) et la maladie cœliaque. La société fusionnée devrait être cotée à Nasdaq sous le symbole CLYD lors de la clôture, dont la finalisation est visée pour la première moitié de 2026. Le portefeuille comprend trois actifs en phase clinique et plusieurs jalons de données à court terme; ChemDiv affirme que ses services ont aidé à faire progresser les programmes de découverte vers le clinique en moins de trois ans.
Clywedog Therapeutics (ehemals Barinthus Therapeutics; NASDAQ: BRNS) und Barinthus haben eine definitive Fusionsvereinbarung unterzeichnet, um Clywedog Therapeutics, Inc. zu bilden. ChemDiv wird weiterhin chemische, rechnerische und klinische Pharmakologie-Unterstützung leisten, während das zusammengeschlossene Unternehmen klinisch-phasen Kandidaten in Typ-1-Diabetes (T1D), Typ-2-Diabetes (T2D) und Zöliakie vorantreibt. Das fusionierte Unternehmen wird voraussichtlich nach Abschluss unter dem Ticker CLYD an der Nasdaq gelistet, wobei der Abschluss der Transaktion für die erste Hälfte 2026 angestrebt wird. Das Portfolio umfasst drei klinische Assets und mehrere nahegelegene Datenmeilensteine; ChemDiv sagt, dass seine Dienstleistungen geholfen haben, Entdeckungsprogramme in die Klinik zu bringen in weniger als drei Jahren.
شركة Clywedog Therapeutics (سابقاً Barinthus Therapeutics؛ NASDAQ: BRNS) و Barinthus قد وقّعتا اتفاق دمج نهائي لتشكيل Clywedog Therapeutics, Inc. وستواصل ChemDiv توفير الدعم في الكيمياء والحوسبة والدواء السريري مع تقدم الشركة المدمجة في تطوير المرشحات في داء السكري من النوع 1 (T1D)، وداء السكري من النوع 2 (T2D) ومرض السيلياك. ستُدرج الشركة المدمجة في ناسداك تحت الرمز CLYD عند الإغلاق، مع إغلاق الصفقة المتوقع في النصف الأول من 2026. المحفظة تشمل ثلاثة أصول في المرحلة السريرية والعديد من معالم البيانات القريبة؛ تقول ChemDiv إن خدماتها ساعدت في انتقال برامج الاكتشاف إلى العيادة في أقل من ثلاث سنوات.
- Planned Nasdaq listing under ticker CLYD upon closing
- Portfolio includes three clinical-stage assets with near-term milestones
- Transaction closing targeted for first half of 2026
- ChemDiv-supported programs progressed from discovery to clinic in less than three years
- Pipeline focus on T1D, T2D, and celiac disease
- None.
Insights
Merger plus vendor continuity supports clinical advancement and preserves development momentum; watch near-term data milestones and closing timing.
The transaction combines Barinthus and Clywedog into Clywedog Therapeutics, Inc., keeping ChemDiv as an active R&D supplier for chemistry, computational modeling, pharmacology and CMC work that previously helped advance programs into the clinic in
Key dependencies and risks include the successful closing targeted for
Concrete items to watch are the merger close timing, the specific near-term clinical data readouts for the three assets, and any disclosure of integration plans or changes to existing CMC timelines; monitor developments through
ChemDiv's ongoing collaboration includes accelerated CMC research, AI-enabled pharmacology, computational modeling, and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023–2024. ChemDiv's medicinal chemistry, in vitro and in vivo biology, and pharmacology services were instrumental in differentiating:
MEN PPI inhibitors – first-in-class candidates that enhance islet cell proliferation and demonstrate therapeutic potential in T2D.
TYK2 inhibitors – best-in-class compounds that reduce pro-inflammatory cytokine signaling, preserving islet cell function to prevent and treat T1D.
Together with Clywedog's other partners, ChemDiv enabled the rapid progression of both programs from discovery to clinic in less than three years.
Roman Timakhov, Research Director at ChemDiv, commented:
"We're proud to support the exceptional teams at Barinthus Bio and Clywedog. As they combine complementary strengths in immunology and metabolism, our integrated platform — AI-curated design, on-demand medicinal chemistry, and translational biology, pharmacology, and CMC — will continue transforming bold scientific hypotheses into differentiated drugs, faster."
Barinthus–Clywedog Combination
Barinthus Biotherapeutics and Clywedog Therapeutics have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. The combined company brings together leading expertise in immunology and metabolic disease with three clinical-stage assets and multiple near-term data milestones. Leadership will include executives from both organizations, with transaction closing targeted for the first half of 2026.
About Barinthus Biotherapeutics
Barinthus Bio is a clinical-stage biopharmaceutical company developing immunotherapeutics designed to guide the immune system toward tolerance in autoimmune and inflammatory diseases. The company rebranded from Vaccitech plc in 2023.
About Clywedog Therapeutics
Clywedog is a clinical-stage biopharmaceutical company focused on metabolic and autoimmune diseases, with lead programs in type 1 and type 2 diabetes.
About ChemDiv
ChemDiv is a fully integrated discovery partner from target to clinic, offering a library of over 12 million screening compounds, 2 trillion feasible chemistries for rational drug design, thousands of pre-designed chemical tool libraries, 70,000 building blocks, and a catalog of 45,000 inhibitors and drugs. Its services include custom medicinal chemistry, CMC, AI-powered CADD, computational pharmacology, lead optimization, translational biology, and clinical pharmacology support.
For further information, please contact:
Bill Farley
CEO of ChemDiv
Bfarley@chemdiv.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemdiv-continues-rd-services-support-for-clywedog-therapeutics-following-merger-with-barinthus-therapeutics-302593839.html
SOURCE ChemDiv
FAQ
What did Clywedog and Barinthus announce on October 24, 2025 regarding a merger (BRNS)?
When is the Barinthus–Clywedog transaction expected to close and list as CLYD?
How many clinical-stage assets will the combined Clywedog company hold after the merger (BRNS to CLYD)?
What role will ChemDiv play after the Barinthus and Clywedog merger announcement?
Which therapeutic areas will Clywedog prioritize after the merger (BRNS/CLYD)?
What acceleration achievements does ChemDiv cite in support of Clywedog programs?
